focus -WSS

focus

author：explore 2025-09-27 22:48:39 - browse：4

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Surgery pushed Ben Carson to fame

WSS

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Unique patient identifier: Experts argue the benefits, pitfalls

Readout Newsletter: Bristol, Sangamo, Gilead, and more

President Biden's budget: Here's what you might have missed

Readout LOUD: Venture capital, Gilead, and more M&A

hotspot

focus

focus

United colonoscopy coverage change 'may cost lives,' doctors say

HHS secretary Becerra pressed on Change HealthCare cyberattack

George Santos makes 1st court appearance after pleading not guilty to 13 counts

EPA limits use of carcinogenic gas for sterilizing medical devices

Peter Hotez and the public health issue of online harassment

UCLA team creates talking throat patch for voice disorders

Peter Hotez and the public health issue of online harassment

Ebola: Gilead Sciences antiviral shows promise as new treatment

Apple is now the first public company to be valued at $3 trillion

As AI in medicine takes off, can 'human in the loop' prevent harm?

hotspot

What’s missing from the debate over nursing home staff minimums

HHS secretary Becerra pressed on Change HealthCare cyberattack

Pushing for an NIH office for post

Readout LOUD: Venture capital, Gilead, and more M&A

A single Democrat is willing to weaken Medicare negotiation power

Surgery pushed Ben Carson to fame

hotspot

knowledge

focus

focus